Body Mass Index: An Unreliable Adiposity Indicator for Predicting Outcomes of Liver Transplantation Due to Hepatocellular Carcinoma.
Autor: | Czarnecka, Kinga, Czarnecka, Paulina, Tronina, Olga, Bączkowska, Teresa, Durlik, Magdalena |
---|---|
Předmět: |
BODY mass index
IMMUNOSUPPRESSIVE agents DATA analysis SCIENTIFIC observation KRUSKAL-Wallis Test LOGISTIC regression analysis TREATMENT effectiveness RETROSPECTIVE studies PREOPERATIVE care MULTIVARIATE analysis PRE-tests & post-tests KAPLAN-Meier estimator SURGICAL complications ONE-way analysis of variance STATISTICS DISEASE relapse PROGRESSION-free survival CONFIDENCE intervals DATA analysis software LIVER transplantation HEPATOCELLULAR carcinoma BIOMARKERS HISTOLOGY OVERALL survival PROPORTIONAL hazards models REGRESSION analysis PATIENT aftercare EVALUATION DISEASE risk factors |
Zdroj: | Gastrointestinal Disorders; Sep2024, Vol. 6 Issue 3, p607-621, 15p |
Abstrakt: | Obesity is a well-documented risk factor for the development of hepatocellular carcinoma (HCC) in the general population. The applicability of these findings to liver recipients is uncertain, and the results of available data have not been unanimous. The objective of the current study was to investigate the impact of the pre-operative body mass index (BMI) on oncological outcomes of liver transplantation due to HCC. Methods: This observational retrospective study enrolled all patients with histologically confirmed HCC who underwent liver transplantation from a deceased donor in our centre between 2008 and 2018. Results: Overall, 83 patients were enrolled and were subsequently stratified according to their pre-operative BMI into three groups: patients with normal body weight (n = 53), patients with overweight (n = 23), patients with obesity (n = 7). Overall tumour recurrence was 12%. BMI failed to predict the 5-year recurrence-free survival (p = 0.55), risk of tumour recurrence (p = 0.314) and overall 5-year survival (p = 0.19) in liver recipients. Conclusions: BMI was proven to be an unreliable surrogate measure of obesity for predicting oncological outcomes among liver recipients. Other obesity indices should be referenced to assess cancer-related prognosis more accurately in these groups of patients. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |